Cefditoren Pivoxil CH
Cefditoren Pivoxil CH Uses, Dosage, Side Effects, Food Interaction and all others data.
Cefditoren Pivoxil CH inhibits the synthesis of bacterial cell wall. It has high affinity to penicillin-binding proteins (PBPs) in various bacteria, showing a bactericidal effect.
Cefditoren Pivoxil CH pivoxil is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Cefditoren Pivoxil CH is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. Cefditoren Pivoxil CH is effective against Staphylococcus aureus (methicillin-susceptible strains, including b-lactamase-producing strains), penicillin-susceptible strains of Staphylococcus aureus and Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae (including b-lactamase-producing strains), Haemophilus parainfluenzae (including b-lactamase-producing strains), Moraxella catarrhalis (including b-lactamase-producing strains), Streptococcus agalactiae, Streptococcus Groups C and G, and Streptococcus, viridans group (penicillin-susceptible and -intermediate strains).
Trade Name | Cefditoren Pivoxil CH |
Availability | Discontinued |
Generic | Cefditoren |
Cefditoren Other Names | Cefditoren, Cefditoreno |
Related Drugs | amoxicillin, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin, Augmentin |
Type | |
Formula | C19H18N6O5S3 |
Weight | Average: 506.578 Monoisotopic: 506.050079786 |
Protein binding | Binding of cefditoren to plasma proteins averages 88% from in vitro determinations, and is concentration-independent at cefditoren concentrations ranging from 0.05 to 10 mg/mL. |
Groups | Approved, Investigational |
Therapeutic Class | Third generation Cephalosporins |
Manufacturer | |
Available Country | Japan |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Cefditoren Pivoxil CH is used for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below:
- Acute Bacterial Exacerbation of Chronic Bronchitis
- Community Acquired Pneumonia
- Pharyngitis
- Tonsillitis
- Uncomplicated Skin and Skin-Structure Infections
Cefditoren Pivoxil CH is also used to associated treatment for these conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Bacterial Infections, Community Acquired Pneumonia (CAP), Streptococcal Pharyngitis, Streptococcal tonsillitis, Uncomplicated skin and subcutaneous tissue bacterial infections
How Cefditoren Pivoxil CH works
The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefditoren Pivoxil CH is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.
Dosage
Cefditoren Pivoxil CH dosage
Community-Acquired Pneumonia: 400 mg twice daily for 14 days.
Acute Exacerbation of Chronic Bronchitis: 400 mg twice daily for 10 days.
Pharyngotonsillitis and Acute Sinusitis: 200 mg twice daily for 10 days.
Uncomplicated Skin and Soft Structure Infections: 200 mg twice daily for 10 days.
Cefditoren Pivoxil CH should be taken after meals.
Side Effects
The most common side effects of Cefditoren Pivoxil CH are diarrhea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, abnormal dreams, allergic reaction, anorexia, constipation, dizziness, dry mouth and fever.
Toxicity
Information on cefditoren pivoxil overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. In acute animal toxicity studies, cefditoren pivoxil when tested at the limit oral doses of 5100 mg/kg in rats and up to 2000 mg/kg in dogs did not exhibit any health effects of concern.
Precaution
Cefditor should be prescribed with caution in individuals with a history of gastrointestinal diseases, particularly colitis. Dosage adjustment is only necessary in severe renal failure (creatinine clearance< 30 ml/min)
Interaction
Co-administration of a single dose of an antacid and H2 receptor antagonists may reduce the oral absorption of cefditoren pivoxil. As with other beta-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren.
Food Interaction
- Avoid multivalent ions. Avoid antacids containing magnesium and aluminum hydroxides when possible, otherwise separate the administration of antacids and this drug by several hours.
[Moderate] ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of cefditoren pivoxil.
According to the manufacturer, administration of cefditoren pivoxil following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 50% and 70%, respectively, compared to administration in the fasting state.
The absolute bioavailability of cefditoren pivoxil is approximately 14% under fasting conditions and 16% when given with a low-fat meal.
MANAGEMENT: To ensure maximal oral absorption, cefditoren pivoxil should be administered with or immediately after a meal.
Cefditoren Pivoxil CH Drug Interaction
Unknown: 5-hydroxytryptophan, 5-hydroxytryptophan, acetaminophen, acetaminophen, aspirin, aspirin, alprazolam, alprazolam, glimepiride, glimepiride, amoxicillin / clavulanate, amoxicillin / clavulanate, acetaminophen, acetaminophen, multivitamin, multivitamin, cholecalciferol, cholecalciferol, diclofenac, diclofenac
Cefditoren Pivoxil CH Disease Interaction
Major: colitis, carnitine deficiencyModerate: renal dysfunction, dialysis, liver disease, seizure disorders
Volume of Distribution
- 9.3 ± 1.6 L
Elimination Route
Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Under fasting conditions, the estimated absolute bioavailability of cefditoren pivoxil is approximately 14%. The absolute bioavailability of cefditoren pivoxil administered with a low fat meal (693 cal, 14 g fat, 122 g carb, 23 g protein) is 16.1 ± 3.0%.
Half Life
Mean terminal elimination half-life is 1.6 ± 0.4 hours in young healthy adults.
Clearance
- renal cl=4-5 L/h [oral administration]
Elimination Route
Pivalate is mainly eliminated (>99%) through renal excretion, nearly exclusively as pivaloylcarnitine.
Pregnancy & Breastfeeding use
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. Cefditoren Pivoxil CH should be used during pregnancy only if clearly needed.
Lactation: Animal studies show that Cefditoren Pivoxil CH excreted in breast milk. Caution should be exercised when Cefditoren Pivoxil CH is administered to nursing women.
Contraindication
Contraindicated in patients hypersensitive to drug or other cephalosporins. Also contraindicated in patients with carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency. Because cefditoren tablets contain sodium caseinate, a milk protein, don't give to patients hypersensitive to milk protein (as distinct from those with lactose intolerance).
Acute Overdose
Information on Cefditoren Pivoxil CH overdosage in humans is not available. However, with other ß-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of Cefditoren Pivoxil CH from the body, particularly if renal function is compromised.
Storage Condition
Store in a cool (below 25° C) and dry place protected from light.
Innovators Monograph
You find simplified version here Cefditoren Pivoxil CH
Cefditoren Pivoxil CH contains Cefditoren see full prescribing information from innovator Cefditoren Pivoxil CH Monograph, Cefditoren Pivoxil CH MSDS, Cefditoren Pivoxil CH FDA label